Shots:

• Pacira acquires MyoScience- in all stock transaction for $220M. MyoScience to receive $120M upfront and $100M as regulatory and commercial milestones. The transaction is expected to close in Apr’2019
• The focus of an acquisition is to strengthen Pacira’s footprints in post-surgical analgesics by adding Myoscience’s iovera system to Pacira’s lead candidate Exparel
• Pacira is planning to change its name to Pacira BioSciences- Inc. to reflect its broad portfolio and expect to complete the acquisition in H2’20

Ref: Pacira | Image: MassDevice